Archives
-
Norepinephrine–Angiotensin II Conversion in Shock
2026-09-16
This post-hoc ARAMIS analysis estimated a clinically useful norepinephrine-to-angiotensin II conversion ratio in patients with vasodilatory hypotension. The findings support a 10:1 conversion for norepinephrine bitartrate while highlighting the need to account for formulation, prior angiotensin receptor blocker exposure, and the limitations of small observational subgroups.
-
NSC-23766: Rac GTPase Inhibitor Workflows
2026-09-16
NSC-23766 enables controlled Rac1 perturbation across breast cancer, endothelial barrier, and glucose-transport assays. This workflow-centered guide explains how to separate pathway effects from nonspecific toxicity and how the 2026 GPR81/FARP1 study expands Rac1-focused experimental design into metabolic research.
-
7-Ethyl-10-hydroxycamptothecin Assay Guide
2026-09-15
This scenario-based guide explains how 7-Ethyl-10-hydroxycamptothecin, also known as SN-38, can support reproducible viability, proliferation, apoptosis, and cell-cycle studies. It covers mechanism, solvent compatibility, protocol controls, interpretation, and selection of SKU N2133 for advanced colon cancer research.
-
Oleanolic Acid: Mechanism and Liposome Workflows
2026-09-15
Oleanolic acid is a research triterpenoid associated with inducible nitric oxide synthase induction and cyclooxygenase-2 signaling. Current evidence supports its use as an antiviral research compound and as a liposome formulation analyte, but neither activity establishes clinical efficacy.
-
SU5416 (Semaxanib): VEGFR2 Research Guide
2026-09-14
SU5416, also called Semaxanib, is a selective VEGFR2 research inhibitor used to study VEGF-induced angiogenesis inhibition and tumor vascularization suppression. It also acts as an aryl hydrocarbon receptor (AHR) agonist and is used in defined cancer, immune-modulation, and pulmonary-hypertension model workflows.
-
VEGFC–Macrophage Signaling in NASH Fibrosis
2026-09-14
This study identifies a hepatocyte-derived VEGFC–VEGFR-3–CCL2/CCR2 axis that promotes inflammatory macrophage recruitment and limits Ly6Chigh-to-Ly6Clow macrophage transition during high-fat diet-induced hepatic fibrosis. Pharmacological inhibition, hepatocyte-specific Vegfc deletion, human clinical data, and cell-based assays together position VEGFC suppression as a mechanistic component of naringin-mediated protection.
-
N2703: Biosynthesis-Informed Assay Design
2026-09-13
3-(1-methylpyrrolidin-2-yl)pyridine (N2703) can be used as an investigational chemical perturbation when assay identity, stereochemistry, exposure, and readouts are carefully controlled. This article connects recent nicotine-biosynthesis findings with more rigorous decisions for cellular signaling and molecular mechanism studies.
-
Lidocaine With Epinephrine Shortage: Evidence and Solutions
2026-09-12
Bodie, Brodell, and Helms interpret the persistent US lidocaine-with-epinephrine shortage as the result of manufacturer attrition compounded by an epinephrine supply bottleneck. Their practice-focused analysis proposes dose reduction, safer stewardship of multidose and prefilled preparations, controlled dilution, and contingency planning while highlighting the clinical disadvantages of replacing vasoconstrictor-containing anesthetic with plain lidocaine.
-
Cyclic Pifithrin-α Hydrobromide in Mechanistic Assays
2026-09-12
Cyclic Pifithrin-α hydrobromide is a research-grade p53 inhibitor for dissecting stress responses, apoptosis, and transcriptional control. This article develops a cautious assay framework connecting p53 perturbation with the Ca2+-CGRP/SP-Piezo2 findings reported in trigeminal neuralgia research.
-
Phosphatase Inhibitor Cocktail 1: Assay Guide
2026-09-11
Learn how Phosphatase Inhibitor Cocktail 1 (100X in DMSO), SKU K1012, helps preserve phosphorylation states during lysate preparation for signaling, viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers compatibility, handling, interpretation, storage, and practical vendor-selection criteria.
-
SAR131675: From Kinase Assay to Fibrosis Biology
2026-09-11
Explore how SAR131675, a selective VEGFR-3 inhibitor, connects biochemical selectivity with lymphangiogenesis, angiogenesis, and the hepatocyte–macrophage axis in fibrosis research. This article provides a causal assay framework rather than a conventional compound overview.
-
Angiotensin (1-7): Applied Research Workflows
2026-09-10
Build reproducible Angiotensin (1-7) experiments across Mas-receptor signaling, renal fibrosis, colitis, and receptor-binding assays. This guide combines formulation controls with pathway-aware readouts and a careful translation of emerging spike–AXL binding data.
-
Tyrothricin Workflows for Membrane-Disruption Research
2026-09-10
Tyrothricin is a peptide antibiotic mixture suited to orthogonal studies of microbial viability, membrane damage, and cross-kingdom antimicrobial activity. This research-focused guide combines practical assay workflows with troubleshooting and a cautious translation of mechanistic lessons from recent neurobiology research.
-
PSA-CD56/Siglec-7 Immune Evasion in ccRCC
2026-09-09
The reference study identifies polysialylated CD56 as a glyco-immune checkpoint that engages Siglec-7 on CD8 T cells, suppressing cytokine production and promoting T-cell apoptosis in clear cell renal cell carcinoma. Its combination of glycoform-specific mechanistic experiments, immune profiling, and NCAM1 genetic ablation provides a framework for studying glycosylation-linked immunotherapy resistance.
-
Isorhamnetin Oocyte Maturation Workflow
2026-09-09
Translate Isorhamnetin biology into a controlled oocyte-maturation workflow that connects polar body extrusion with ROS, apoptosis, endoplasmic reticulum, and PI3K/Akt readouts. The design emphasizes solvent control, dose-ranging, and mechanism-aware troubleshooting rather than treating this flavonoid as a nonspecific antioxidant.